The U.S. Food and Drug ... approved Cobenfy without a “black box” warning on the regulatory label for a greater risk of death in elderly patients who have psychosis related to dementia.
No new treatments for schizophrenia have been approved in nearly three decades ... The company is currently studying the drug in Alzheimer’s-related psychosis, and next year plans to start ...
which is currently under FDA review. Approval for a monthly IV dose of Leqembi is also being sought. The Alzheimer’s Drug Discovery Foundation (ADDF) also welcomed the approval, saying it would ...
The two FDA-approved drugs have demonstrated in clinical trials the capability to slow cognitive decline by several months, The Washington Post reported Oct. 8.
The safety and effectiveness of donanemab—an Alzheimer's drug recently approved by the US Food & Drug Administration (FDA)—is called into question in an investigation published by The BMJ.
The medication, Cobenfy, combines two drugs and is taken as a twice-daily pill. The U.S. Food and Drug Administration (FDA) on Thursday ... brain chemical that aids memory, learning and attention ...
Medicare could save millions of dollars every year by changing the way they package Alzheimer's medication.
74-year-old Norman Colpitts is living with the early stages of Alzheimer's disease, but he's taking lecanemab. That's one of two FDA-approved drugs to *slow the progression of Alzheimer's disease.
UTHealth Houston is the first institution in Houston to administer an FDA-approved drug, Kisunla (donanemab-azbt), for the ...
Tribune Alzheimer’s drug disappointment. People with Down syndrome have the highest prevalence for developing Alzheimer’s ...
26 (UPI) --The U.S. Food and Drug Administration has approved a new drug for adults ... A new diagnosis of Alzheimer's or other dementia often spurs a person to move from their home, new research ...
27, 2024 – In a breakthrough for people living with schizophrenia, the FDA has approved ... and difficulty with thinking, memory, and decision-making. Unlike older drugs, which target dopamine ...